<DOC>
	<DOCNO>NCT00562289</DOCNO>
	<brief_summary>A patent foramen ovale ( PFO ) find frequently patient ischemic stroke control subject . Therapeutic option prevent stroke recurrence include antiplatelet drug , oral anticoagulant , transcatheter closure foramen . However , publish study show convincingly superiority one strategy prevent stroke recurrence . The aim randomize clinical trial ass whether chronic anticoagulation one hand transcatheter hand superior chronic antiplatelet therapy prevent stroke recurrence .</brief_summary>
	<brief_title>Patent Foramen Ovale Closure Anticoagulants Versus Antiplatelet Therapy Prevent Stroke Recurrence</brief_title>
	<detailed_description>Secondary prevention stroke patient PFO subject considerable debate . Therapeutic option include antiplatelet drug , oral anticoagulant , transcatheter closure foramen . There publish study show convincingly superiority one strategy prevent stroke recurrence . All therapeutic option risk unless randomise trial define treat ( anything ) , long , could end expose patient unnecessary complication treatment . The primary objective study ass whether chronic anticoagulation ( INR 2 3 ) one hand endovascular treatment hand superior chronic antiplatelet therapy prevent stroke recurrence young ( 16 60 year ) patient PFO ( &gt; 30 microbubbles associate atrial septal aneurysm ) otherwise unexplained ischaemic stroke . Secondary objective study : - evaluate safety three therapeutic option , term major drug- , device- procedure-related complication , order allow benefit/risk assessment therapeutic option population . - ass rate technical success effectiveness endovascular procedure treat PFO ASA .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Aneurysm</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Foramen Ovale , Patent</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Apixaban</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<mesh_term>Antivitamins K</mesh_term>
	<mesh_term>Anticoagulants</mesh_term>
	<criteria>Male female , 16 &lt; = age &lt; = 60 an . Recent ( &lt; = 6 month ) ischemic stroke document CTsan MRI ( whatever duration symptom : shorter longer 24 hour ) . Modified Rankin score &lt; =3 . Absence identifiable cause stroke Presence PFO least one follow characteristic : righttoleft shunt &gt; 30 microbubbles , rest provocative manoeuvre , TTE ou TOE associate ASA ( base ≥ à 15 mm , total excursion &gt; à 10 mm ) TOE Informed consent . Any identifiable cause ischemic stroke PFO . Isolated atrial septal defect atrial septal defect associate PFO significant lefttoright shunt require closure . Previous surgical endovascular treatment PFO ASA . Known suspect pregnancy ( beta hCG test must perform inclusion ) . Women breastfeed . Inability comply treatment followup requirement study . No affiliation national health service . Presence medical problem would either lead inability complete trial interfere assessment outcome . Participation another study . Unable understand full meaning informed consent . Related medical treatment trial : Longterm oral anticoagulation antiplatelet therapy indicate another disease . Contraindication antiplatelet therapy oral anticoagulant : 3arm trial : contraindication aspirin clopidogrel antivitamins K 2arm trial ( closure vs antiplatelet therapy ) : contraindication aspirin clopidogrel 2arm trial ( antivitamins K v antiplatelet therapy : contraindication antivitamins K antiplatelet drug Increased risk bleeding , severe hepatic insufficiency , current peptic ulceration , proliferative diabetic retinopathy , history severe systemic bleeding ( e.g . gastrointestinal bleeding , gross hematuria , intraocular bleeding , hemorrhagic stroke , intracranial hemorrhage ) , history bleed diathesis coagulopathy . Related endovascular treatment : Infection require antibiotic ( inclusion possible healing , 4 week withdrawal antibiotic ) . Very large multiperforated ASA endovascular treatment deem risky . Presence thrombus occlusion venous access right atrium . Presence inferior vena cava filter . Severe pulmonary hypertension .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Stroke</keyword>
	<keyword>Patent Foramen Ovale</keyword>
	<keyword>Atrial septal aneurysm</keyword>
	<keyword>Antiplatelet therapy</keyword>
	<keyword>Oral anticoagulant</keyword>
	<keyword>Transcatheter closure</keyword>
	<keyword>Migraine</keyword>
</DOC>